Document and Entity Information (USD $)	3 Months Ended
Document and Entity Information (USD $)	Mar. 31, 2013	May 01, 2013	Sep. 28, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Document Type	10-KT
Document Period End Date	Mar. 31, 2013
Amendment Flag	false
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 50,421,992
Entity Common Stock, Shares Outstanding		64,686,919

Consolidated Balance Sheets (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 15,628,000	$ 14,817,000	$ 340,000
Grant receivable	101,000	162,000
Inventory	88,000	360,000	292,000
Deferred financing costs			319,000
Prepaid expenses and other current assets	327,000	527,000	80,000
Total current assets	16,144,000	15,866,000	1,031,000
Fixed Assets - Net	1,045,000	714,000	278,000
Restricted Cash	88,300	88,300
Other Assets - Net	98,000	81,000	100,000
Total assets	17,375,000	16,749,000	1,409,000
Current Liabilities
Accounts payable	641,000	425,000	658,000
Accrued expenses	780,000	981,000	438,000
Deferred revenue	53,000		153,000
Capital lease obligation, current portion	10,000	10,000
Accrued interest payable			24,000
Convertible notes payable			704,000
Warrant liabilities, current	6,898,000	20,619,000
Total current liabilities	8,382,000	22,035,000	1,977,000
Warrant liabilities, non-current			1,267,000
Deferred revenue, net of current portion	9,000
Capital lease obligation, net of current portion	15,000	17,000
Total liabilities	8,406,000	22,052,000	3,244,000
Commitments and Contingencies (see Note 8)
Stockholders' Equity (Deficit)
Common stock, $0.001 par value; 150,000,000 shares authorized, 64,686,919, 58,535,411 and 22,445,254 shares issued and outstanding at March 31, 2013, December 31, 2012 and December 31, 2011, respectively	65,000	59,000	22,000
Additional paid-in capital	75,269,000	44,883,000	4,835,000
Deficit accumulated during the development stage	(66,365,000)	(50,245,000)	(6,692,000)
Total stockholders' equity (deficit)	8,969,000	(5,303,000)	(1,835,000)
Total Liabilities and Stockholders' Equity (Deficit)	$ 17,375,000	$ 16,749,000	$ 1,409,000

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Common stock, shares issued	64,686,919	58,535,411	22,445,254
Common stock, shares outstanding	64,686,919	58,535,411	22,445,254

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		12 Months Ended			71 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2013
Revenue
Product				$ 224		$ 224
Collaborations	98	120	1,035	688	75	1,896
Grants	117		162	57	528	943
Total Revenue	215	120	1,197	969	603	3,063
Cost of product revenue				121		134
Selling, general, and administrative expenses	2,792	902	7,080	1,733	578	12,539
Research and development expenses	1,448	547	3,436	1,420	1,203	8,082
Loss from Operations	(4,025)	(1,329)	(9,319)	(2,305)	(1,178)	(17,692)
Other Income (Expense)
Fair value of warrant liabilities in excess of proceeds received		(19,019)	(19,019)			(19,019)
Change in fair value of warrant liabilities	(12,034)	(13,506)	(9,931)	(7)		(21,972)
Financing transaction costs in excess of proceeds received		(2,130)	(2,130)			(2,130)
Loss on inducement to exercise warrants			(1,904)			(1,904)
Loss on disposal of fixed assets			(158)			(158)
Interest expense	(65)	(1,088)	(1,088)	(2,067)	(161)	(3,471)
Interest income	4		5			11
Other expense		(9)	(9)	(4)		(30)
Total Other Income (Expense)	(12,095)	(35,752)	(34,234)	(2,078)	(161)	(48,673)
Net Loss	$ (16,120)	$ (37,081)	$ (43,553)	$ (4,383)	$ (1,339)	$ (66,365)
Net loss per common share - basic and diluted	$ (0.26)	$ (1.17)	$ (1.01)	$ (0.19)	$ (0.09)
Weighted average number of shares used in computing net loss per share - basic and diluted	61,750,157	31,591,663	43,149,657	22,925,694	14,620,140

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock	Additional Paid-in Capital	Deficit Accumulated During the Development Stage
Beginning balance at Apr. 19, 2007
Beginning balance, Shares at Apr. 19, 2007
Issuance of common stock
Stock-based compensation expense
Net Loss
Ending balance at Dec. 31, 2007
Ending balance, Shares at Dec. 31, 2007
Issuance of common stock to founders		2,000	(2,000)
Issuance of common stock to founders, Shares		1,730,000
Issuance of restricted common stock		12,000	(12,000)
Issuance of restricted common stock, Shares		12,628,000
Stock-based compensation expense	2,000		2,000
Net Loss	(98,000)			(98,000)
Ending balance at Dec. 31, 2008	(96,000)	14,000	(12,000)	(98,000)
Ending balance, Shares at Dec. 31, 2008		14,358,000
Issuance of restricted common stock, Shares		130,000
Stock-based compensation expense	2,000		2,000
Net Loss	(872,000)			(872,000)
Ending balance at Dec. 31, 2009	(966,000)	14,000	(10,000)	(970,000)
Ending balance, Shares at Dec. 31, 2009		14,488,000
Issuance of restricted common stock, Shares		219,000
Stock-based compensation expense	4,000		4,000
Net Loss	(1,339,000)			(1,339,000)
Ending balance at Dec. 31, 2010	(2,301,000)	14,000	(6,000)	(2,309,000)
Ending balance, Shares at Dec. 31, 2010		14,707,000
Issuance of restricted common stock, Shares		61,000
Issuance of common stock through conversion of notes payable	3,490,000	8,000	3,482,000
Issuance of common stock through conversion of notes payable, Shares		7,677,000
Issuance of warrants to consultants/Warrants issued with convertible notes and conversion of notes payable	1,111,000		1,111,000
Beneficial conversion feature of convertible notes payable	239,000		239,000
Stock-based compensation expense	9,000		9,000
Net Loss	(4,383,000)			(4,383,000)
Ending balance at Dec. 31, 2011	(1,835,000)	22,000	4,835,000	(6,692,000)
Ending balance, Shares at Dec. 31, 2011		22,445,000
Issuance of restricted common stock		1,000	(1,000)
Issuance of restricted common stock, Shares		1,380,000
Issuance of common stock through conversion of notes payable, Shares	224,064
Issuance of warrants to consultants/Warrants issued with convertible notes and conversion of notes payable	890,000		890,000
Stock-based compensation expense	1,435,000		1,435,000
Loss on inducement to exercise warrants	1,904,000		1,904,000
Net Loss	(43,553,000)			(43,553,000)
Issuance of common stock in connection with merger		6,000	(6,000)
Issuance of common stock in connection with merger, Shares		6,000,000
Issuance of common stock through private placements in connection with reverse merger	13,723,000	14,000	13,709,000
Issuance of common stock through private placements in connection with reverse merger, Shares		13,723,000
Issuance of common stock through conversion of notes payable and accrued interest in connection with merger	1,526,000	2,000	1,524,000
Issuance of common stock through conversion of notes payable and accrued interest in connection with merger, Shares		1,525,000
Costs associated with merger	(13,723,000)		(13,723,000)
Issuance of common stock from warrant exercises, net	10,991,000	14,000	10,977,000
Issuance of common stock from warrant exercises, net, Shares		13,424,000
Restricted stock forfeitures, Shares		(186,000)
Issuances of common stock from stock option exercise	18,000		18,000
Issuances of common stock from stock option exercise, Shares	224,064	224,000
Warrant liability removed due to exercise of warrants	23,321,000		23,321,000
Ending balance at Dec. 31, 2012	(5,303,000)	59,000	44,883,000	(50,245,000)
Ending balance, Shares at Dec. 31, 2012		58,535,000
Issuance of restricted common stock, Shares		55,000
Stock-based compensation expense	848,000		848,000
Expense related to modification of warrants	65,000		65,000
Warrant liability reclassified to equity	1,886,000		1,886,000
Net Loss	(16,120,000)			(16,120,000)
Issuance of common stock from warrant exercises, net	3,724,000	6,000	3,718,000
Issuance of common stock from warrant exercises, net, Shares		6,131,000
Restricted stock forfeitures, Shares	(24,690)	(34,000)
Issuances of common stock from stock option exercise, Shares	927,981
Warrant liability removed due to exercise of warrants	23,869,000		23,869,000
Ending balance at Mar. 31, 2013	$ 8,969,000	$ 65,000	$ 75,269,000	$ (66,365,000)
Ending balance, Shares at Mar. 31, 2013		64,687,000

Consolidated Statements of Cash Flows (USD $)	3 Months Ended		12 Months Ended			71 Months Ended
Consolidated Statements of Cash Flows (USD $)	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2013
Cash Flows From Operating Activities
Net loss	$ (16,120,000)	$ (37,081,000)	$ (43,553,000)	$ (4,383,000)	$ (1,339,000)	$ (66,365,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	0	896,000	896,200	603,800		2,084,000
Loss on disposal of fixed assets			158,000			158,000
Depreciation and amortization	80,000	17,000	195,000	68,000	59,000	431,000
Amortization of deferred financing costs		319,000	319,000	119,000		438,000
Amortization of warrants issued for services	261,000		556,000			817,000
Interest accrued on convertible notes payable		12,000	12,000	232,000		495,000
Warrants issued in connection with exchange agreement				528,000		528,000
Loss on inducement to exercise warrants			1,904,000			1,904,000
Expense associated with warrant modification	65,000					65,000
Stock-based compensation	848,000	4,000	1,435,000	9,000	4,000	2,300,000
Fair value of warrant liabilities in excess of proceeds		19,019,000	19,019,000			19,019,000
Change in fair value of warrant liabilities	12,034,000	13,506,000	9,931,000	7,000		21,972,000
Increase (decrease) in cash resulting from changes in:
Grants receivable	61,000		(162,000)	60,000	(55,000)	(101,000)
Inventory		(45,000)	(459,000)	(224,000)	(68,000)	(751,000)
Prepaid expenses and other current assets	(61,000)	(65,000)	(101,000)	(69,000)	(2,000)	(255,000)
Accounts payable	216,000	(217,000)	(233,000)	373,000	230,000	641,000
Accrued expenses	(201,000)	(37,000)	543,000	132,000	83,000	780,000
Deferred revenue	62,000	116,000	(153,000)	46,000	107,000	62,000
Accrued interest					161,000
Net cash used in operating activities	(2,755,000)	(3,556,000)	(9,693,000)	(1,914,000)	(820,000)	(15,778,000)
Cash Flows From Investing Activities
Restricted cash deposits		(38,000)	(88,000)			(88,000)
Purchases of fixed assets	(137,000)	(6,000)	(357,000)	(46,000)	(48,000)	(921,000)
Purchases of intangible assets	(19,000)			(65,000)	(5,000)	(114,000)
Net cash used in investing activities	(156,000)	(44,000)	(445,000)	(111,000)	(53,000)	(1,123,000)
Cash Flows From Financing Activities
Proceeds from issuance of convertible notes payable				2,543,000	992,000	4,630,000
Proceeds from issuance of common stock and exercise of warrants, net	3,724,000	13,723,000	24,714,000			28,438,000
Proceeds from exercise of stock options			18,000			18,000
Proceeds from issuance of related party notes payable				225,000	25,000	250,000
Repayment of related party notes payable				(250,000)		(250,000)
Repayment of convertible notes and interest payable		(110,000)	(110,000)			(110,000)
Principal payments on capital lease obligations	(2,000)		(7,000)			(9,000)
Deferred financing costs				(438,000)		(438,000)
Net cash provided by financing activities	3,722,000	13,613,000	24,615,000	2,080,000	1,017,000	32,529,000
Net Increase in Cash and Cash Equivalents	811,000	10,013,000	14,477,000	55,000	144,000	15,628,000
Cash and Cash Equivalents at Beginning of Period	14,817,000	340,000	340,000	285,000	141,000
Cash and Cash Equivalents at End of Period	15,628,000	10,353,000	14,817,000	340,000	285,000	15,628,000
Supplemental Disclosures of Cash Flow Information:
Interest		10,000	10,000			10,000
Income Taxes		$ 1,000	$ 1,000	$ 1,000	$ 1,000	$ 3,000

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Consolidated Statements of Cash Flows [Abstract]
Issuance restricted Common stock to certain employees, advisors and consultants				219,369
Warrants and related beneficial conversion feature valued			$ 823,000
Warrants issued in connection with convertible notes payable			1,260,000
Issuance of common stock to note holders		1,525,387	7,676,828
Convertible Notes principal balance		1,500,000	3,030,000
Accrued interest		25,000	460,000
Issued warrants in connection with the Reverse Merger and the Private Placement		32,743,000
Purchased equipment through capital lease		34,000
Transferred amount of inventory to fixed assets	272,000	391,000
Issued warrants to purchase shares of common stock for consulting services, shares		650,000
Issued warrants to purchase shares of common stock for consulting services		890,000
Warrant liability reduced	23,869,000	23,321,000
Warrant reclassified as equity instruments	$ 1,886,000

Description of Business and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2013

Description of Business and Summary of Significant Accounting Policies [Abstract]

Description of Business and Summary of Significant Accounting Policies

2. Description of Business and Summary of Significant Accounting Policies

A summary of significant accounting policies, consistently applied in the preparation of the accompanying consolidated financial statements follows:

Nature of operations and basis of presentation

Organovo Holdings, Inc., (the “Company”), through its wholly-owned subsidiary, Organovo, Inc., a Delaware corporation, has devoted substantially all of its resources to product development, raising capital, and building infrastructure. The Company is developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

All of the Company’s potential products are in research and development phases and as of March 31, 2013 the Company has not generated revenue from its planned principal operations. The Company does earn revenue from research and development agreements with collaborators and grants from governmental entities. Accordingly, the Company is considered to be in the development stage.

Reverse merger transaction

On February 8, 2012, Organovo, Inc., a privately held Delaware corporation, merged with and into Organovo Acquisition Corp., a wholly-owned subsidiary of Organovo Holdings, Inc., a publicly traded Delaware corporation, with Organovo, Inc. surviving the merger as a wholly-owned subsidiary of the Company (the “Merger”). As a result of the Merger, the Company acquired the business of Organovo, Inc., and will continue the existing business operations of Organovo, Inc.

Simultaneously with the Merger, on February 8, 2012 (the “closing date”), all of the issued and outstanding shares of Organovo, Inc.’s common stock converted, on a 1 for 1 basis, into shares of the Company’s common stock, par value $0.001 per share. Also, on the closing date, all of the issued and outstanding options to purchase shares of Organovo, Inc.’s common stock and other outstanding warrants to purchase Organovo, Inc.’s common stock, and all of the issued and outstanding bridge warrants to purchase shares of Organovo, Inc.’s common stock, converted on a 1 for 1 basis, into options, warrants and new bridge warrants to purchase shares of the Company’s common stock.

Immediately following the consummation of the Merger: (i) the former security holders of Organovo, Inc. common stock had an approximate 75% voting interest in the Company and the Company stockholders retained an approximate 25% voting interest, (ii) former executive management team of Organovo, Inc. remained as the only continuing executive management team for the Company, and (iii) the Company’s ongoing operations consist solely of the ongoing operations of Organovo, Inc. Based primarily on these factors, the Merger was accounted for as a reverse merger and a recapitalization in accordance with accounting principles generally accepted in the United States (“GAAP”). As a result, these financial statements reflect the historical results of Organovo, Inc. prior to the Merger, and the combined results of the Company following the Merger. The par value of Organovo, Inc. common stock immediately prior to the Merger was $0.0001 per share. The par value subsequent to the Merger is $0.001 per share, and therefore the historical results of Organovo, Inc. prior to the Merger have been retroactively adjusted to affect the change in par value.

In connection with three separate closings of a private placement transaction completed in connection with the Merger (the “Private Placement”), the Company received gross proceeds of approximately $5.0 million, $1.8 million and $6.9 million on closings on February 8, 2012, February 29, 2012 and March 16, 2012, respectively. In 2011, the Company received $1.5 million from the purchase of 6% convertible notes which were automatically converted into 1,500,000 shares of common stock, plus 25,387 shares for accrued interest of $25,387 on the principal, on February 8, 2012.

The cash transaction costs related to the Merger were approximately $2.1 million.

Before the Merger, Organovo Holdings’ Board of Directors and stockholders adopted the 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of 6,553,986 shares of the Company’s common stock to executive officers, directors, advisory board members and employees. In addition, Organovo Holdings assumed and adopted Organovo, Inc.’s 2008 Equity Incentive Plan, which provided for the issuance of 896,256 shares of common stock, for total shares available for issuance under these plans of 7,450,242.

Liquidity

As of March 31, 2013, the Company had an accumulated deficit of approximately $66.4 million. The Company also had negative cash flows from operations of approximately $2.8 million during the three months ended March 31, 2013.

On February 8, 2012, the Company received gross proceeds of approximately $5.0 million from the initial closing of a private placement offering in conjunction with the Merger (the “Private Placement”). On February 29, 2012 and March 16, 2012, the Company completed two additional closings of its Private Placement receiving gross proceeds of approximately $1.8 million and $6.9 million respectively.

In December 2012, the Company consummated a warrant tender offer to the holders of outstanding warrants to purchase approximately 14.5 million shares of the Company’s common stock. In accordance with the tender offer, for those warrant holders that elected to participate, this resulted in a reduction of the exercise price of the warrants from $1.00 per share to $0.80 per share of common stock in cash, shortened the exercise period of the warrants so that they expired concurrently with the tender offer, and removed the price-based anti-dilution provisions contained in the warrants. The Company completed the tender offer on December 21, 2012, resulting in approximately 9.6 million warrants being exercised for gross proceeds of approximately $7.7 million. In connection with the transaction, the Company recognized an expense for the inducement to exercise the warrants of approximately $1.9 million. The Company also incurred approximately $0.4 million in placement agent fees, legal costs, and other related fees, which have been recognized as an offset to the proceeds received from the warrant exercises.

On February 5, 2013, the Company provided a Notice of Redemption to affected warrant holders, of approximately 2.4 million warrant shares, that they would have until March 14, 2013 to exercise their outstanding warrants at $1.00 per share. Thereafter, any warrants that remained unexercised would have been automatically redeemed by the Company at a redemption price of $0.0001 per share of common stock then issuable upon exercise of the redeemed warrant. As of March 14, 2013, all redeemable warrants had been exercised for net proceeds of approximately $2.3 million. During the three months ended March 31, 2013, the Company also received approximately $1.4 million of additional proceeds from the exercise of other warrants unrelated to the Redemption Notification.

Through March 31, 2013, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, and through revenue derived from grants or collaborative research agreements. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next 12 months.

The Company will need additional capital to further fund product development and commercialization of its human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intends to cover its future operating expenses through cash on hand, through additional financing from existing and prospective investors, and from revenue derived from grants and collaborative research agreements. However, we may not be successful in obtaining funding from new or existing collaborative research agreements. In addition, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. Further, the NIH has notified all grant recipients that due to the current Congressional budget sequestration, the NIH may not be able to issue continuation awards, or it may be required to negotiate a reduction in the scope of existing awards to meet the constraints imposed. Additionally, plans for new grants or cooperative agreements may be re-scoped, delayed, or canceled depending on the nature of the work and the availability of resources. As a result, we cannot assure you that we will receive the funding under our existing NIH grants, and we may not be successful in securing additional grants from the NIH in the future.

Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Use of estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the consolidated financial statements include those assumed in computing the valuation of warrants and conversion features, revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets.

Financial instruments

For certain of the Company’s financial instruments, including cash and cash equivalents, grants receivable, inventory, prepaid expenses and other assets, accounts payable, accrued expenses, deferred revenue, capital lease obligations, and convertible notes payable, the carrying amounts are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.

Cash and cash equivalents

The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Derivative financial instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency.

The Company reviews the terms of convertible debt and equity instruments it issues to determine whether there are derivative instruments, including an embedded conversion option that is required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where a host instrument contains more than one embedded derivative instrument, including a conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Also, in connection with the sale of convertible debt and equity instruments, the Company may issue freestanding warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity.

Derivative instruments are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.

The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method.

Restricted cash

As of March 31, 2013 and December 31, 2012, the Company had approximately $88,300 of restricted cash deposited with a financial institution. $38,300 is held in certificates of deposit to support a letter of credit agreement related to the facility lease entered into during 2012. The additional $50,000 is held by the financial institution as a guarantee for the Company’s commercial credit cards.

Grant receivable

Grant receivable represents the amount due from the National Institutes of Health (“NIH”) under a research grant. The Company considers the grant receivable to be fully collectible; and accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.

Inventory

Inventories are stated at the lower of the cost or market (first-in, first-out). Inventory at March 31, 2013 consisted of approximately $88,000 in raw materials. Inventory at December 31, 2012 consisted of approximately $196,000 in finished goods, $60,000 work-in-process and $104,000 in raw materials. Inventory at December 31, 2011 consisted of approximately $204,000 in finished goods, $24,000 in work-in-process and $64,000 in raw materials.

The Company provides inventory allowances based on excess or obsolete inventories determined based on anticipated use in the final product. There was no obsolete inventory reserve as of March 31, 2013, December 31, 2012 or December 31, 2011.

Deferred financing costs

As of March 31, 2013 and December 31, 2012, there were no deferred financing costs. As of December 31, 2011, deferred financing costs consisted of approximately $140,000 associated with the Merger transaction and approximately $179,000 associated with convertible notes as part of the private placement offering that was initiated in the fourth quarter of 2011. The deferred financing costs related to the private placement offering were being amortized over the life of the convertible notes and were fully amortized to expense upon conversion of the convertible notes on February 8, 2012. The deferred financing costs associated with the Merger transaction were recorded as an offset to the proceeds received, with the amount in excess of the proceeds received expensed at the effective Merger date.

Fixed assets and depreciation

Property and equipment are carried at cost. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term. The estimated useful lives of the fixed assets range between two and five years.

Impairment of long-lived assets

In accordance with authoritative guidance the Company reviews its long-lived assets, including property and equipment and other assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates whether future undiscounted net cash flows will be less than the carrying amount of the assets and adjusts the carrying amount of its assets to fair value. Management has determined that no impairment of long-lived assets occurred in the period from inception through March 31, 2013.

Fair value measurement

Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company has issued warrants, of which some are classified as derivative liabilities as a result of the terms in the warrants that provide for down-round protection in the event of a dilutive issuance. The Company uses Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions (see Note 5). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models we use to value the warrants, including the Company’s current stock price, the remaining life of the warrants, the volatility of the Company’s stock price, and the risk free interest rate. Future changes in these factors will have a significant impact on the computed fair value of the warrant liability. As such, we expect future changes in the fair value of the warrants to continue to vary significantly from quarter to quarter.

The estimated fair values of the liabilities measured on a recurring basis are as follows:


	Fair Value Measurements at March 31, 2013 and December 31, 2012 and 2011 (in thousands):
	Balance at March 31, 2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Warrant liability	$	6,898		—		—	$	6,898

	Balance at December 31, 2012		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Warrant liability	$	20,619		—		—	$	20,619

	Balance at December 31, 2011		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Warrant liability	$	1,267		—		—	$	1,267

The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for 2011 and 2012 and the three months ended March 31, 2013:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)


	Warrant Derivative Liability ($000’s)
Balance at December 31, 2010	$	—
Issuances		1,260
Adjustments to estimated fair value		7

Balance at December 31, 2011		1,267
Issuances		32,742
Adjustments to estimated fair value		9,931
Warrant liability removal due to settlements		(23,321	)

Balance at December 31, 2012		20,619
Issuances		—
Adjustments to estimated fair value		12,034
Warrant liability removal due to settlements		(23,869	)
Warrant liability reclassified to equity		(1,886	)

Balance at March 31, 2013	$	6,898

Research and development

Research and development expenses, including direct and allocated expenses, consist of independent research and development costs, as well as costs associated with sponsored research and development. Research and development costs are expensed as incurred.

Income taxes

Deferred income taxes are recognized for the tax consequences in future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.

Revenue recognition

The Company’s revenues are derived from collaborative research agreements, NIH and U.S. Treasury Department Grants, the sale of bioprinter related products and services, and license agreements.

The Company recognizes revenue when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) services have been rendered or product has been delivered; (iii) price to the customer is fixed and determinable; and (iv) collection of the underlying receivable is reasonably assured.

Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of March 31, 2013, December 31, 2012 and December 31, 2011, the Company had approximately $62,000, $0 and $152,500, respectively, in deferred revenue related to its collaborative research programs.

Product Revenue

The Company recognizes product revenue at the time of shipment to the customer, provided all other revenue recognition criteria have been met. The Company recognizes product revenues upon shipment to distributors, provided that (i) the price is substantially fixed or determinable at the time of sale; (ii) the distributor’s obligation to pay the Company is not contingent upon resale of the products; (iii) title and risk of loss passes to the distributor at time of shipment; (iv) the distributor has economic substance apart from that provided by the Company; (v) the Company has no significant obligation to the distributor to bring about resale of the products; and (vi) future returns can be reasonably estimated. For any sales that do not meet all of the above criteria, revenue is deferred until all such criteria have been met.

Research and Development Revenue Under Collaborative Agreements

The Company’s collaboration revenue consists of license and collaboration agreements that contain multiple elements, including non-refundable upfront fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the elements are separable, whether there are determinable fair values and whether there is a unique earnings process associated with each element of a contract.

The Company recognizes revenue from research funding under collaboration agreements when earned on a “proportional performance” basis as research hours are incurred. The Company performs services as specified in each respective agreement on a best-efforts basis, and is reimbursed based on labor hours incurred on each contract. The Company initially defers revenue for any amounts billed or payments received in advance of the services being performed and recognizes revenue pursuant to the related pattern of performance, based on total labor hours incurred relative to total labor hours estimated under the contract.

In December 2010, the Company entered into a 12 month research contract agreement with a third party, whereby the Company was engaged to perform research and development services on a fixed-fee basis for approximately $600,000. Based on the proportional performance criteria, the Company recognized approximately $150,000 and $450,000 in revenue related to the contract during the years ended December 31, 2012 and 2011, respectively. Total revenue recognized on the contract from inception through March 31, 2013 was approximately $600,000.

In October 2011, the Company entered into a research contract agreement with a third party, whereby the Company is performing research and development services on a fixed-fee basis for $1,365,000. The agreement included an initial payment to the Company of approximately $239,000 with remaining payments expected to occur over a twenty-one month period. On November 27, 2012, the agreement was amended to include additional research and development services, for an additional $135,000, bringing the total contract value to $1,500,000. This extends the original contract (which runs concurrently) from twenty-one months to twenty-eight months. The Company recorded approximately $97,000, $885,000 and $239,000 for the three months ended March 31, 2013 and the years ended December 31, 2012 and 2011, respectively, in revenue related to the research contract in recognition of the proportional performance achieved. Total revenue recognized on the contract from inception through March 31, 2013 was approximately $1,221,000.

Revenue Arrangements with Multiple Deliverables

The Company occasionally enters into revenue arrangements that contain multiple deliverables. Judgment is required to properly identify the accounting units of the multiple deliverable transactions and to determine the manner in which revenue should be allocated among the accounting units. Moreover, judgment is used in interpreting the commercial terms and determining when all criteria of revenue recognition have been met for each deliverable in order for revenue recognition to occur in the appropriate accounting period. For multiple deliverable agreements, consideration is allocated at the inception of the agreement to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using VSOE of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable.

The Company recognizes revenue for delivered elements only when it determines there are no uncertainties regarding customer acceptance. While changes in the allocation of the arrangement consideration between the units of accounting will not affect the amount of total revenue recognized for a particular sales arrangement, any material changes in these allocations could impact the timing of revenue recognition, which could affect the Company’s results of operations.

The Company expects to periodically receive license fees for non-exclusive research licensing associated with funded research projects. License fees under these arrangements are recognized over the term of the contract or development period as it has been determined that such licenses do not have stand-alone value.

NIH and U.S. Treasury Grant Revenues

During 2010, the U.S. Treasury awarded the Company two one-time grants totaling approximately $397,000 for investments in qualifying therapeutic discovery projects under section 48D of the Internal Revenue Code. The grants cover reimbursement for qualifying expenses incurred by the Company in 2010 and 2009. The proceeds from these grants are classified in “Revenues — Grants” for the year ended December 31, 2010 and the period from inception through March 31, 2013.

During 2012, 2010 and 2009, the NIH awarded the Company three research grants totaling approximately $558,000. Revenues from the NIH grants are based upon internal and subcontractor costs incurred that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors and as the Company incurs internal expenses that are related to the grants. Revenue recognized under these grants for the three months ended March 31, 2013 and the years ended December 31, 2012, 2011 and 2010 was approximately $117,000, $162,000, $57,000 and $131,000, respectively. Total revenue recorded under these grants from inception through March 31, 2013 was approximately $546,000.

Stock-based compensation

The Company accounts for stock-based compensation in accordance with the Financial Accounting and Standards Board’s ASC Topic718, Compensation — Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).

The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at their estimated fair value as they vest.

Comprehensive income (loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the three months ended March 31, 2013 and the years ended December 31, 2012, 2011 and 2010, and for the period April 19, 2007 (inception) through March 31, 2013, the comprehensive loss was equal to the net loss.

Net loss per share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, and the assumed issuance of common stock under restricted stock units, shares subject to repurchase and warrants as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended March 31, 2013 or 2012, or the years ended December 31, 2012, 2011 or 2010 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Total common stock equivalents that were excluded from computing diluted net loss per share were approximately 8.9 million, 25.8 million, 15.2 million, 6.4 million and 0 for the three months ended March 31, 2013 and 2012 and the years ended December 31, 2012, 2011 and 2010, respectively.

Reclassifications

Certain reclassifications were made to the 2011 financial statements in order to conform to the presentation of the financial statements for 2012 and subsequent periods. The reclassifications did not have any effect on previously reported net loss or stockholders’ equity (deficit).

Fixed Assets

3 Months Ended

Mar. 31, 2013

Fixed Assets [Abstract]

Fixed Assets

3. Fixed Assets

Fixed assets consisted of the following (in thousands):


	March 31, 2013			December 31, 2012			December 31, 2011
Laboratory equipment	$	1,168		$	759		$	345
Leasehold improvements		—			—			34
Computer software and equipment		114			114			28
Furniture and fixtures		33			33			19

		1,315			906			426

Less accumulated depreciation and amortization		(270	)		(192	)		(148	)

	$	1,045		$	714		$	278

Depreciation and amortization expense for three months ended March 31, 2013 and the years ended December 31, 2012, 2011 and 2010 was approximately $78,000, $188,000, $63,000 and $57,000, respectively. Depreciation and amortization expense was approximately $414,000 for the period from April 19, 2007 (inception) through March 31, 2013.

Description of Business and Summary of Significant Accounting Policies (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability			$ 1,267
Significant Other Unobservable Inputs (Level 3) [Member] \| Warrant [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability	6,898	20,619	1,267
Fair Value, Measurements, Recurring [Member] \| Warrant [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability	6,898	20,619	1,267
Fair Value, Measurements, Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member] \| Warrant [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability
Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member] \| Warrant [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability
Fair Value, Measurements, Recurring [Member] \| Significant Other Unobservable Inputs (Level 3) [Member] \| Warrant [Member]
Estimated fair values of the liabilities measured on a recurring basis
Warrant liability	$ 6,898	$ 20,619	$ 1,267

Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)	1 Months Ended				2 Months Ended	3 Months Ended		12 Months Ended			47 Months Ended	71 Months Ended							1 Months Ended	3 Months Ended	12 Months Ended		71 Months Ended	1 Months Ended	12 Months Ended		71 Months Ended		3 Months Ended		3 Months Ended				3 Months Ended	0 Months Ended	1 Months Ended		3 Months Ended	1 Months Ended		3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended			37 Months Ended	71 Months Ended
	Dec. 31, 2012	Mar. 16, 2012	Feb. 29, 2012	Feb. 08, 2012	Aug. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Mar. 31, 2013	Feb. 07, 2012	Oct. 31, 2011	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Apr. 19, 2007	Oct. 31, 2011 Research and Development Services [Member]	Mar. 31, 2013 Research and Development Services [Member]	Dec. 31, 2012 Research and Development Services [Member]	Dec. 31, 2011 Research and Development Services [Member]	Mar. 31, 2013 Research and Development Services [Member]	Dec. 31, 2010 12 month research contract agreement [Member]	Dec. 31, 2012 12 month research contract agreement [Member]	Dec. 31, 2011 12 month research contract agreement [Member]	Mar. 31, 2013 12 month research contract agreement [Member]	Mar. 31, 2013 Common Stock [Member]	Mar. 31, 2013 Maximum [Member]	Dec. 31, 2011 Maximum [Member]	Mar. 31, 2013 Minimum [Member]	Dec. 31, 2011 Minimum [Member]	Feb. 08, 2012 Convertible Notes Payable [Member]	Dec. 31, 2011 Convertible Notes Payable [Member]	Mar. 31, 2013 2012 Equity Incentive Plan [Member]	Mar. 16, 2012 Merger transition [Member]	Feb. 29, 2012 Merger transition [Member]	Feb. 08, 2012 Merger transition [Member]	Mar. 31, 2013 Merger transition [Member] Private_Placement	Feb. 08, 2012 Outstanding Principal Assumed on Acquisition [Member]	Feb. 08, 2012 Accrued Interest Assumed on Acquisition [Member]	Mar. 31, 2013 U.S. Treasury [Member]	Dec. 31, 2010 U.S. Treasury [Member] Grants	Mar. 31, 2013 NHLBI [Member]	Dec. 31, 2012 NHLBI [Member]	Dec. 31, 2011 NHLBI [Member]	Dec. 31, 2010 NHLBI [Member]	Dec. 31, 2012 NHLBI [Member] Grants	Mar. 31, 2013 NHLBI [Member]
Description Of Business And Summary Of Significant Accounting Policies (Textual) [Abstract]
Number of private placement transactions																																							3
Convertible notes, interest rate					20.00%																									10.00%		8.00%	6.00%
Total gross proceeds of approximately		$ 6,900,000	$ 1,800,000	$ 5,000,000																																$ 6,900,000	$ 1,800,000	$ 5,000,000
Convertible notes converted into shares of common stock																																								1,500,000	25,387
Issuance of common stock																																			6,553,986
Maturity of highly liquid investment																													90 days
Deferred financing costs	0					0		0	140,000		140,000	0																						179,000
Useful life of fixed assets, range																													5 years		2 years
Term of research contract agreement with third party																								12 months
Revenue related to research contract																				97,000	885,000	239,000			150,000	450,000
Total revenue recognized from inception on the contract						215,000	120,000	1,197,000	969,000	603,000		3,063,000											1,221,000				600,000
Research and development services on a fixed-fee basis																			1,365,000					600,000
Initial payment to the Company from Agreement																			239,000
Remaining payments expected to occur over																			21 months
Grants						117,000		162,000	57,000	528,000		943,000																														397,000		117,000	162,000	57,000	131,000	558,000	546,000
Deferred revenue related to its collaborative research programs						53,000			153,000		153,000	53,000								62,000	0	152,500	62,000
Number of grants issued																																											2					3
Redemption to affected warrant holders						2,400,000
Five-year warrants to purchase shares, exercise price per share	1.00							1.00						1.00														1.00	3.24		0.90
Redemption price of common stock issuable						$ 0.0001
Warrant reclassified as equity instruments						2,300,000
Description of Business and Summary of Significant Accounting Policies (Additional Textual) [Abstract]
Conversion ratio into common stock on merger				0.0001
Common stock, par value	$ 0.001			$ 0.001		$ 0.001		$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.0001
Other than common stock business acquisition conversion ratio				0.0001
Former security holders common stock voting interest						75.00%
Company's stockholders retained voting interest						25.00%
Proceeds from issuance of convertible notes payable				1,500,000	740,000				2,543,000	992,000	2,390,000	4,630,000
Accrued interest				25,387				25,000	460,000
Cash transaction costs related to the Merger approximately						2,100,000
Equity Incentive Plan, shares						896,256						896,256
Stock Issued During Period, Shares, Share-based Compensation, Gross						7,450,242						7,450,242
Accumulated deficit	(5,303,000)					8,969,000		(5,303,000)	(1,835,000)	(2,301,000)	(1,835,000)	8,969,000			(966,000)	(96,000)
Outstanding warrants to purchase								14,500,000
Exercise price of warrant Amended	0.80							0.80
Warrant Tender Offer								9,600,000
Aggregate proceeds of Warrants tendered	7,700,000							32,743,000
Redemption price of common stock issuable						$ 0.0001
Total common stock equivalents						8,900,000	25,800,000	15,200,000	6,400,000	0
Cash flow from operations						(2,755,000)	(3,556,000)	(9,693,000)	(1,914,000)	(820,000)		(15,778,000)
Expiration date of Warrant Tender Offer						Dec. 21, 2012
Additional proceeds from exercise of warrants						1,400,000
Restricted Cash	88,300					88,300		88,300				88,300
Restricted cash	38,300							38,300
Additional restricted cash						50,000						50,000
Inventory of finished goods	196,000							196,000	204,000		204,000
Inventory of work in process	60,000							60,000	24,000		24,000
Inventory of raw materials	104,000					88,000		104,000	64,000		64,000	88,000
Obsolete inventory reserve	0					0		0	0		0	0
Impairment of long-lived assets												0
Estimated useful life of the fixed assets						The estimated useful life of the fixed assets range between two and five years.
Dilutive effect						$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Fee for additional research and development services						135,000
Total contract value						1,500,000
Total stock reserved for future issuance						9,628,711						9,628,711
Recognized expenses of warrants								1,900,000
Proceeds received from exercise of warrants								$ 400,000

Fixed Assets (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fixed Assets
Laboratory equipment	$ 1,168	$ 759	$ 345
Leasehold improvements			34
Computer software and equipment	114	114	28
Furniture and fixtures	33	33	19
Fixed assets, gross	1,315	906	426
Less accumulated depreciation and amortization	(270)	(192)	(148)
Net	$ 1,045	$ 714	$ 278

Fixed Assets (Details Textual) (USD $)	3 Months Ended	12 Months Ended			71 Months Ended
Fixed Assets (Details Textual) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2013
Fixed Assets (Textual) [Abstract]
Depreciation and amortization expense	$ 78,000	$ 188,000	$ 63,000	$ 57,000	$ 414,000

Accrued Expenses (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of Accrued Expenses
Accrued compensation	$ 386	$ 720	$ 317
Other accrued expenses	124	73	92
Deferred rent	270	188	29
Total Other Income (Expense)	$ 780	$ 981	$ 438

Derivative Liability (Details) (USD $)	3 Months Ended	12 Months Ended
Derivative Liability (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Assumptions used to value derivative liabilities at closing dates of the Private Placements
Expected volatility		110.13%
Warrant Derivative Liability [Member]
Assumptions used to value derivative liabilities at closing dates of the Private Placements
Closing price per share of common stock	$ 3.68	$ 2.60
Exercise price per share	$ 1.00	$ 1.00	$ 1.00
Expected volatility	88.80%	92.90%	109.80%
Risk-free interest rate	0.57%	0.54%	0.83%
Dividend yield
Remaining expected term of underlying securities (years)	3 years 10 months 17 days	4 years 1 month 28 days	5 years

Convertible Notes Payable (Details) (USD $)	1 Months Ended			2 Months Ended		3 Months Ended		12 Months Ended			47 Months Ended	71 Months Ended	12 Months Ended					12 Months Ended	2 Months Ended		12 Months Ended		1 Months Ended	12 Months Ended				2 Months Ended	12 Months Ended		3 Months Ended	1 Months Ended	3 Months Ended
Convertible Notes Payable (Details) (USD $)	Feb. 29, 2012 Investment	Feb. 08, 2012	Oct. 31, 2011	Nov. 30, 2011	Aug. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012 Private_Placement	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Mar. 31, 2013	Dec. 31, 2012 Maximum [Member] Securities	Mar. 31, 2013 Maximum [Member]	Dec. 31, 2011 Maximum [Member]	Mar. 31, 2013 Minimum [Member]	Dec. 31, 2011 Minimum [Member]	Dec. 31, 2011 Common Stock [Member]	Nov. 30, 2011 Convertible Notes Payable [Member]	Sep. 18, 2011 Convertible Notes Payable [Member]	Dec. 31, 2011 Convertible Notes Payable [Member] Maximum [Member]	Dec. 31, 2011 Convertible Notes Payable [Member] Minimum [Member]	Sep. 18, 2011 Private Placement [Member]	Dec. 31, 2012 Private Placement [Member] Warrant	Dec. 31, 2011 Private Placement [Member]	Mar. 31, 2013 Private Placement [Member]	Dec. 31, 2012 Private Placement [Member] Common Stock [Member]	Nov. 30, 2011 Warrant [Member]	Dec. 31, 2012 Warrant [Member] Common_Stock	Dec. 31, 2011 Warrant [Member]	Mar. 31, 2013 Warrant [Member] Local Bridge [Member]	Feb. 29, 2012 Unsecured Debt [Member] Convertible Notes Payable [Member]	Mar. 31, 2013 Unsecured Debt [Member] Convertible Notes Payable [Member]	Dec. 31, 2011 Unsecured Debt [Member] Convertible Notes Payable [Member]
Convertible Notes Payable (Textual) [Abstract]
Convertible notes, interest rate					20.00%										10.00%		8.00%		6.00%	6.00%														10.00%
Funds raised through loans consisting of Convertible notes		$ 1,500,000			$ 740,000				$ 2,543,000	$ 992,000	$ 2,390,000	$ 4,630,000
Debt instrument maturity year range start																						2011
Debt instrument maturity year range end																					2018
Percentage of per share fair market value of total consideration					75.00%
Warrant Discount									583,700
Debt Discount									1,260,300		1,260,300
Fair value of warrants								110.13%																							109.84%
Dividend yield																														0.00%	0.00%
Principal amount			3,030,000
Accrued interest converted			459,800			459,800
Accrued interest converted price range														$ 0.75		$ 0.27
Interest Expense						65,000	1,088,000	1,088,000	2,067,000	161,000		3,471,000
Common stock, shares issued			7,676,828															7,676,828
Purchase shares of common stock for issued warrants								21,347,182	2,909,750		2,909,750															610,155				1,309,750
Interest rate																														1.11%	1.12%
Warrants classified as equity instruments						527,600						527,600
Warrants Expiration Period						5 years
Warrants exercisable price, per share			1.00					1.00						3.24		0.90							1.00			1.00
Unsecured Convertible Note, outstanding																																		100,000
Unsecured Convertible Note, maturity date																																	2014-04
Convertible note and accrued interest repaid																																110,000
Private placement offering, number of units of securities								16,000,000															30
Private placement offering, price per unit																							$ 50,000
Private placement offering, aggregate purchase price																							1,500,000
Each unit consisted of a convertible note in the principal amount																							50,000
Period of warrants				5 years																			5 years
Each unit consisted of a convertible note in the principal shares																							50,000
Convertible Notes issued																			1,500,000
Exercise price of warrants, per share																												$ 1.00
Expiration of warrant																												5 years
Amortization of debt discount						0	896,000	896,200	603,800			2,084,000
Issuance of notes, recorded discount for beneficial conversion feature									239,000																					239,700
Payment to Private placement agent																									195,000
Private placement offering, number of units of securities Issued													8,000,000
Each unit of Common Stock																													1
Warrant																								1
Closings under the private placement								3
Proceeds under Private Placement, total net								11,593,066
Shares of Common Stock and warrants issued																											13,722,600
Purchase of share of its Common Stock																								15,247,987
Share issued for warrant																								1,525,387
Issued warrants to placement agent for purchase of common stock								6,099,195
Maturity date of convertible Notes issued																			Mar. 30, 2012
Convertible Notes Payable (Additional Textual) [Abstract]
Five-year warrants to purchase shares				1,500,000
Notes converted	1,525,387
Interest expense for amortization of debt discount till date												1,500,000
Derivative liabilities exceeded the proceeds, amount						19,019,400
Proceeds under Private Placement, total gross								13,722,600
Expense allowance paid to placement agent								411,678
Total cash commissions paid to placement agent and selected dealers								1,372,260
Private placement securities per unit price								1.00
Derivative liabilities estimated at fair value								$ 32,742,000
Registration Rights Agreement term								90 days
Monetary penalties charge on failure of Effectiveness Deadline								0.50%
Penalty period								30 days

Stockholders' Equity (Details)	3 Months Ended	12 Months Ended
Stockholders' Equity (Details)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Summary of the Company's restricted stock award activity
Beginning balance, Unvested, Number of Shares	1,162,044	1,111,295	4,283,082	7,319,904	12,562,486
Granted, Number of Shares	55,000	1,380,000	61,406	219,369	130,422	12,627,697
Vested, Number of Shares	(196,612)	(1,143,735)	(3,233,193)	(3,256,191)	(5,373,004)	(65,211)
Cancelled / forfeited, Number of Shares	(34,690)	(185,516)
Ending balance, Unvested, Number of Shares	985,742	1,162,044	1,111,295	4,283,082	7,319,904	12,562,486

Stockholders' Equity (Details 1) (USD $)	3 Months Ended	12 Months Ended
Stockholders' Equity (Details 1) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of stock option activity
Options Outstanding, Beginning Balance	2,690,586	896,256
Granted, Options Outstanding	927,981	2,023,394	896,256
Cancelled, Options Outstanding		(5,000)
Exercised, Options Outstanding	(927,981)	(224,064)
Options Outstanding, Ending Balance	3,618,567	2,690,586	896,256
Vested and Exercisable, Options Outstanding	144,841
Weighted-Average Exercise Price, Options Beginning Balance	$ 1.48	$ 0.08
Options granted, Weighted-Average Exercise Price	$ 3.93	$ 1.95	$ 0.08
Options cancelled, Weighted-Average Exercise Price		$ 2.25
Options exercised, Weighted-Average Exercise Price		$ 0.08
Weighted-Average Exercise Price, Options Ending Balance	$ 2.11	$ 1.48	$ 0.08
Vested and Exercisable, Weighted-Average Exercise Price	$ 2.56
Options Exercised, Aggregate Intrinsic Value		$ 564,641
Aggregate Intrinsic Value, Options Ending Balance	5,909,154	3,041,476
Vested and Exercisable, Aggregate Intrinsic Value	$ 184,961

Stockholders' Equity (Details 2) (USD $)	3 Months Ended	12 Months Ended
Stockholders' Equity (Details 2) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fair value of employee stock options
Dividend yield
Volatility	96.83%	96.22%	111.00%
Risk-free interest rate	1.19%	0.89%	1.07%
Expected life of options	6 years 26 days	6 years 18 days	5 years
Weighted average grant date fair value	$ 3.04	$ 1.50	$ 0.06

Stockholders' Equity (Details 3) (USD $)	3 Months Ended	12 Months Ended
Stockholders' Equity (Details 3) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of warrant activity
Options Outstanding, Beginning Balance	2,690,586	896,256
Granted, Options Outstanding	927,981	2,023,394	896,256
Expired / Cancelled Options Outstanding		5,000
Exercised, Options Outstanding	(927,981)	(224,064)
Options Outstanding, Ending Balance	3,618,567	2,690,586	896,256
Weighted-Average Exercise Price, Options Beginning Balance	$ 1.48	$ 0.08
Granted, Weighted-Average Exercise Price	$ 3.93	$ 1.95	$ 0.08
Expired / Cancelled Weighted-Average Exercise Price		$ 2.25
Exercised, Weighted-Average Exercise Price		$ 0.08
Weighted-Average Exercise Price, Options Ending Balance	$ 2.11	$ 1.48	$ 0.08
Warrant [Member]
Summary of warrant activity
Options Outstanding, Beginning Balance	11,374,445	2,909,750
Granted, Options Outstanding		21,997,182	2,909,750
Expired / Cancelled Options Outstanding
Exercised, Options Outstanding	(7,090,556)	(13,532,487)
Options Outstanding, Ending Balance	4,283,889	11,374,445	2,909,750
Weighted-Average Exercise Price, Options Beginning Balance	$ 1.08	$ 1.00
Granted, Weighted-Average Exercise Price		$ 1.04	$ 1.00
Expired / Cancelled Weighted-Average Exercise Price
Exercised, Weighted-Average Exercise Price	$ 1.01	$ 0.84
Weighted-Average Exercise Price, Options Ending Balance	$ 1.17	$ 1.08	$ 1.00

Stockholders' Equity (Details 4)	Mar. 31, 2013
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	9,628,711
Warrant [Member]
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	4,283,889
Equity Incentive Plan 2008 [Member]
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	672,192
Equity Incentive Plan 2012 [Member]
Common stock capital shares reserved for future issuance
Common stock reserved for future issuance	4,672,630

Stockholders' Equity (Details Textual) (USD $)	1 Months Ended		3 Months Ended		12 Months Ended					71 Months Ended	3 Months Ended	12 Months Ended			3 Months Ended	12 Months Ended					12 Months Ended				3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended				1 Months Ended	3 Months Ended	12 Months Ended			48 Months Ended	71 Months Ended	3 Months Ended	12 Months Ended			71 Months Ended	3 Months Ended	12 Months Ended			3 Months Ended	12 Months Ended					1 Months Ended	12 Months Ended		1 Months Ended	3 Months Ended	12 Months Ended			48 Months Ended	12 Months Ended		48 Months Ended
Stockholders' Equity (Details Textual) (USD $)	Dec. 31, 2012	Oct. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Mar. 31, 2013	Mar. 31, 2013 Research and Development Expense [Member]	Dec. 31, 2012 Research and Development Expense [Member]	Dec. 31, 2011 Research and Development Expense [Member]	Dec. 31, 2010 Research and Development Expense [Member]	Mar. 31, 2013 General and Administrative Expense [Member]	Dec. 31, 2012 General and Administrative Expense [Member]	Dec. 31, 2011 General and Administrative Expense [Member]	Dec. 31, 2010 General and Administrative Expense [Member]	Dec. 31, 2012 Maximum [Member]	Mar. 31, 2013 Maximum [Member]	Dec. 31, 2012 Minimum [Member]	Mar. 31, 2013 Minimum [Member]	Mar. 31, 2013 Private Placement [Member]	Sep. 18, 2011 Private Placement [Member]	Mar. 31, 2013 Restricted Stock Units (RSUs) [Member]	Dec. 31, 2012 Restricted Stock Units (RSUs) [Member]	Mar. 31, 2013 Warrant [Member]	Dec. 31, 2012 Warrant [Member]	Dec. 31, 2011 Warrant [Member]	Dec. 31, 2012 Warrant [Member] Maximum [Member]	Dec. 31, 2012 Warrant [Member] Minimum [Member]	Feb. 29, 2008 Restricted Stock [Member]	Mar. 31, 2013 Restricted Stock [Member]	Dec. 31, 2012 Restricted Stock [Member]	Dec. 31, 2011 Restricted Stock [Member]	Dec. 31, 2010 Restricted Stock [Member]	Dec. 31, 2011 Restricted Stock [Member]	Mar. 31, 2013 Restricted Stock [Member]	Mar. 31, 2013 Stock Options [Member]	Dec. 31, 2012 Stock Options [Member]	Dec. 31, 2011 Stock Options [Member]	Dec. 31, 2010 Stock Options [Member]	Mar. 31, 2013 Stock Options [Member]	Mar. 31, 2013 Stock Options [Member] Research and Development Expense [Member]	Dec. 31, 2012 Stock Options [Member] Research and Development Expense [Member]	Dec. 31, 2011 Stock Options [Member] Research and Development Expense [Member]	Dec. 31, 2010 Stock Options [Member] Research and Development Expense [Member]	Mar. 31, 2013 Stock Options [Member] General and Administrative Expense [Member]	Dec. 31, 2012 Stock Options [Member] General and Administrative Expense [Member]	Dec. 31, 2011 Stock Options [Member] General and Administrative Expense [Member]	Dec. 31, 2010 Stock Options [Member] General and Administrative Expense [Member]	Dec. 31, 2012 Performance Based Restricted Stock Units (RSUs) [Member]	Mar. 31, 2012 Merger [Member]	Feb. 29, 2008 CEO and three directors [Member]	Dec. 31, 2012 Equity Incentive Plan 2012 [Member]	Jan. 31, 2012 Equity Incentive Plan 2012 [Member]	Apr. 30, 2012 Equity Incentive Plan 2008 [Member]	Mar. 31, 2013 Equity Incentive Plan 2008 [Member]	Dec. 31, 2012 Equity Incentive Plan 2008 [Member]	Oct. 12, 2011 Equity Incentive Plan 2008 [Member]	May 31, 2008 Equity Incentive Plan 2008 [Member]	Dec. 31, 2011 Equity Incentive Plan 2008 [Member] Restricted Stock [Member]	Dec. 31, 2012 Equity Incentive Plan 2008 [Member] Stock Options [Member]	Oct. 12, 2011 Equity Incentive Plan 2008 [Member] Stock Options [Member]	Dec. 31, 2011 Other Plan [Member] Restricted Stock [Member]	Dec. 31, 2012 Agreement with Consultant for Services [Member]
Stockholders' Equity (Textual) [Abstract]
Common stock, shares issued	58,535,411		64,686,919		58,535,411	22,445,254				64,686,919																	6,131,198	13,423,622																									21,247,987
Warrants exercise																											7,090,556	13,532,487
Common stock issued					224,064
Common stock restricted issued number of founder																																																						4
Restricted common stock to founders																																11,779,960					1,258,934																									1,086,662			172,272
Restricted stock vesting conditions																																25% vesting after the first year and the remaining 75% vesting in equal quarterly portions over the following three years																															A quarter of which will vest on the one year anniversary of employment, in May 2012, and the remaining options are vesting ratably over the remaining 36 month term
Portion of restricted common stock vesting After one year																																25.00%
Portion of restricted common stock vesting over three year																																75.00%
Stock Option Granted, Quarterly Vesting Restricted Term																																3 years																							3 years
Common shares authorized to be issued			7,450,242							7,450,242																																														6,553,986					1,521,584
Shares issued during the year																																																										0	0
Termination date of Equity Incentive Plan																																																										Jul. 01, 2018
Termination date of Equity Incentive Plan, Description			10 years
Stock options granted under 2008 equity incentive plan			927,981		2,023,394	896,256																						21,997,182	2,909,750				55,000	200,000																		950,000
Percentage of vesting schedule																										25.00%
Period for vesting schedule over start date																										4 years
Restricted stock cancelled			34,690		185,516																												34,690	185,516
Common stock returned by holders																																	24,690	148,016
Restricted stock units vested during the period			196,612		1,143,735	3,233,193	3,256,191	5,373,004	65,211																50,000	211,250
Stock option granted with immediate vesting																									24,690	83,986
Additional restricted stock Units were forfeited by one staff member upon termination																									10,000	37,500
Unrecognized stock-based compensation expense																																	$ 1,300,000					$ 1,300,000
Equity Incentive Plan, shares			896,256							896,256																																																						896,256
Remaining options vest																																																									36 months
Issuances of common stock from stock option exercise, Shares			927,981		224,064																						7,090,556	13,532,487																											2,023,394
Total employee stock-based compensation recorded as operating expenses											4,000	23,000	0	0	474,000	812,000	3,000	4,000															478,000	835,000	3,000	4,000		1,324,000	370,000	600,000	6,000	0	976,000	58,000	81,000	0	0	312,000	519,000	6,000	0
Research and development expenses			1,448,000	547,000	3,436,000	1,420,000	1,203,000			8,082,000
General and administrative expense			2,792,000	902,000	7,080,000	1,733,000	578,000			12,539,000
Restricted stock forfeitures, shares			24,690																																																				83,986
Stock Option Granted, Restricted portion																																																							124,000
Unrecognized stock-based compensation expense recognition maximum weighted average period																																	2 years 5 months 1 day
Granted incentive stock options to purchase shares of Common stock, exercise price																																																												$ 0.08
Total unrecognized compensation cost related to unvested stock option grants, weighted average period																																							3 years 6 months 0 days
Purchase shares of common stock for issued warrants	21,347,182				21,347,182	2,909,750																	610,155																																											650,000
Estimated fair value of warrants																												890,000
Life of warrants																			5 years		2 years
Volatility rate			96.83%		96.22%	111.00%																								103.80%	79.80%
Risk free factor			1.19%		0.89%	1.07%																								0.63%	0.24%
Warrants exercisable price, per share	1.00	1.00			1.00															3.24		0.90	1.00	1.00						3.24	1.70
Exercise price of warrants before amendment			1.00							1.00
Exercise price of warrants after amendment			0.90							0.90
Issue of common stock shares																											58,220
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance restricted Common stock to certain employees, advisors and consultants			55,000		1,380,000	61,406	219,369	130,422	12,627,697																	230,000
Weighted average remaining contractual term of options exercisable			9 years 6 months 0 days																								3 years 10 months 17 days
Interest Expense			65,000	1,088,000	1,088,000	2,067,000	161,000			3,471,000																	65,000
Stockholders' Equity (Additional Textual) [Abstract]
Common stock issued for conversion		7,676,828
Convertible Notes principal balance		3,030,000
Accrued interest converted		459,800	459,800
Common stock exercised warrants					224,064
Weighted average remaining contractual term of options outstanding			9 years 3 months 29 days
Total unrecognized compensation cost related to unvested stock option grants			4,926,000							4,926,000
Number of warrant exercised	13,259,987		3,852,214		13,259,987	0				3,852,214
Cashless exercise for issuance of common stock	163,635		2,220,764		163,635					2,220,764
Outstanding warrants to purchase					14,500,000
Exercise price of warrant Amended	0.80				0.80
Warrant proceeds					9,600,000
Aggregate proceeds of Warrants tendered	7,700,000				32,743,000
Recognized expenses of warrants					1,900,000
Proceeds received from exercise of warrants					400,000
Exercised cash proceeds			3,850,000	11,356,000
Number of warrant exercised through cashless			3,138,342		272,500
Price earned period					6 months
Recognized expenses of warrants	556,000		261,000		556,000					261,000
Exercised derivative liabilities			6,990,556		13,010,237
Company amendment agreement term year			5 years
Cashless exercise of warrants			100,000							100,000
Research and development expenses			1,448,000	547,000	3,436,000	1,420,000	1,203,000			8,082,000
General and administrative expense			$ 2,792,000	$ 902,000	$ 7,080,000	$ 1,733,000	$ 578,000			$ 12,539,000
Warrants to purchase common stock			600,065							600,065

Commitments and Contingencies (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013
Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year
Fiscal year ended March 31, 2014	$ 479
Fiscal year ended March 31, 2015	493
Fiscal year ended March 31, 2016	506
Fiscal year ended March 31, 2017	170
Fiscal year ended March 31, 2018
Total	$ 1,648

Commitments and Contingencies (Details 1) (Equipment [Member], USD $) In Thousands, unless otherwise specified	Mar. 31, 2013
Equipment [Member]
Agreement to lease certain laboratory equipment under a non-cancelable capital lease, which is included in fixed assets
Lab equipment	$ 34
Less accumulated depreciation	(4)
Net book value	$ 30

Commitments and Contingencies (Details 2) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Future minimum capital lease payments
Fiscal year ended March 31, 2014	$ 11
Fiscal year ended March 31, 2015	11
Fiscal year ended March 31, 2016	4
Total minimum lease payments	26
Amount representing interest	(1)
Present value of minimum lease payments	25
Less current portion	(10)	(10)
Long term portion	$ 15	$ 17

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		12 Months Ended			71 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2013
Commitments and Contingencies (Textual) [Abstract]
Rent expense	$ 105,500	$ 60,200	$ 325,600	$ 145,200	$ 107,500	$ 755,700
Base rent under the lease	38,800					38,800
Base rent escalators	3.00%					3.00%
Lease term with option to extend	48 months
Depreciation Expense	$ 1,700		$ 2,900

Licensing Agreements and Research Contracts (Details) (Licensing Agreements [Member], USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Licensing Agreements [Member]
Schedule of Capitalized license fees
License fees	$ 114,000	$ 95,000	$ 95,000
Less accumulated amortization	(17,000)	(15,000)	(8,000)
License fees, net	$ 97,000	$ 80,000	$ 87,000

Licensing Agreements and Research Contracts (Details Textual) (USD $)	12 Months Ended		3 Months Ended	12 Months Ended		71 Months Ended	1 Months Ended		3 Months Ended	12 Months Ended				1 Months Ended
	Dec. 31, 2010	Mar. 31, 2013	Mar. 31, 2013 Licensing Agreements [Member]	Dec. 31, 2012 Licensing Agreements [Member]	Dec. 31, 2011 Licensing Agreements [Member]	Mar. 31, 2013 Licensing Agreements [Member]	Mar. 31, 2010 University of Missouri [Member]	Mar. 31, 2009 University of Missouri [Member]	Mar. 31, 2013 University of Missouri [Member]	Dec. 31, 2012 University of Missouri [Member]	Dec. 31, 2011 University of Missouri [Member]	Mar. 12, 2010 University of Missouri [Member]	Mar. 24, 2009 University of Missouri [Member]	May 31, 2011 Clemson University [Member] Licensing Agreements [Member]	May 31, 2011 Clemson University [Member] Licensing Agreements [Member] Maximum [Member]	May 31, 2011 Clemson University [Member] Licensing Agreements [Member] Minimum [Member]	Feb. 28, 2013 Becton Dickinson [Member]	May 02, 2011 Other Assets [Member] Clemson University [Member] Licensing Agreements [Member]
Licensing Agreements and Research Contracts (Textual) [Abstract]
License Costs							$ 5,000	$ 25,000						$ 32,500
Royalty fees percentage minimum							1.00%	1.00%						1.50%
Royalty fees percentage maximum							3.00%	3.00%						3.00%
Minimum annual royalty							5,000	25,000							40,000	20,000
Expected expiration year of license agreement								2029
Other Assets amortized			97,000	80,000	87,000	97,000						5,000	25,000					65,000
Additional royalty							12,500
Additional license fee to reimburse future patent costs														32,500
Expected expiration year of license agreement														2024-05
Prior patent costs relating to the license agreements									0	193,500	23,800
Payments to purchase exclusive rights to intellectual property																	18,500
Royalty Expense			0
Amortization expense of licenses	1,500		2,000	7,000	5,200	16,700
Weighted average remaining amortization period for all licenses			12 years
Annual amortization expense of licenses year 1			8,500			8,500
Annual amortization expense of licenses year 2			8,500			8,500
Annual amortization expense of licenses year 3			8,500			8,500
Annual amortization expense of licenses year 4			8,500			8,500
Annual amortization expense of licenses year 5			8,500			8,500
Licensing Agreements and Research Contracts (Additional Textual) [Abstract]
Initial royalty payment due		4,000
Annual royalty payment due		$ 25,000

Income Taxes (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:
Net operating loss carry forwards			$ 1,620
Research and development credits			190
Depreciation and amortization	(1)	(2)	8
Accrued expense and reserves	224	290	107
Stock compensation	743	562
Other, net	1
Total deferred tax assets	967	850	1,925
Valuation allowance	(967)	(850)	(1,925)
Deferred tax assets net

Income Taxes (Details Textual) (USD $)	3 Months Ended	12 Months Ended
Income Taxes (Details Textual) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes (Textual) [Abstract]
Increase/Decrease in valuation allowance	$ 117,000	$ (1,075,000)
Federal and state net operating loss carryforwards expiring year	2028
Federal research tax credit carryforwards expiration period	2028
Accruals for income tax accounting uncertainties	0	0	0
Accrued expense regarding interest or penalties	0	0	0
State net operating loss carryforwards	15,378,000
Federal net operating loss carryforwards	15,382,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Research tax credit carryforwards	292,000
State [Member]
Operating Loss Carryforwards [Line Items]
Research tax credit carryforwards	$ 308,000

Subsequent Events (Details Textual)	3 Months Ended
Subsequent Events (Details Textual)	Mar. 31, 2013
Subsequent Events (Textual) [Abstract]
Warrants to purchase common stock	600,065
Exercise price of warrants before amendment	1.00
Exercise price of warrants after amendment	0.90
Subsequent Event [Member]
Subsequent Events (Textual) [Abstract]
Warrants to purchase common stock	269,657
Exercise price of warrants before amendment	1.00
Exercise price of warrants after amendment	0.85
Extended exercise period	5 years